AI辅助诊断“有价可循”

Core Insights - The National Healthcare Security Administration (NHSA) has released a guideline that includes "AI-assisted diagnosis" as an extension of pathology diagnosis, integrating it into the pricing structure for pathology services [1][2] - The guideline consolidates existing pricing projects into 28 items, with 3 additional charges and 2 expansion items, focusing on various stages such as biopsy sampling, sample processing, and pathological diagnosis [1] - The NHSA aims to promote the application of AI in pathology by guiding local pricing based on the resource investment costs associated with AI-assisted diagnosis, allowing medical institutions to choose whether to adopt this technology and negotiate revenue sharing with companies [1] Industry Implications - Pathology is recognized as the "gold standard" in medical diagnosis, utilizing platforms like cellular pathology and molecular pathology to provide critical insights for clinical treatment plans [1] - The NHSA will guide provincial healthcare security bureaus to establish a unified pricing benchmark across provinces, allowing for adjustments based on local conditions [2]